Home
About
Overview
Sharing Data
ORCID
Help
History (40)
Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohort.
A CD8+ T-lymphocyte-mediated and CD4+ T-lymphocyte-independent autoimmune diabetes of early onset in transgenic mice.
Spleen cell transfusion in the Bio-Breeding/Worcester rat. Prevention of diabetes, major histocompatibility complex restriction, and long-term persistence of transfused cells.
Cadmium
Should We Agree to Disagree on Who May Benefit From ICU Admission?
See All 40 Pages
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Should We Agree to Disagree on Who May Benefit From ICU Admission?
Law AC, Walkey AJ. Should We Agree to Disagree on Who May Benefit From ICU Admission? Crit Care Med. 2019 01; 47(1):133-135.
View in:
PubMed
subject areas
Hospitalization
Humans
Intensive Care Units
Physicians
authors with profiles
Allan Jay Walkey MD, MSc